ArticleFrontiers in medicine2026
Identification of novel protein biomarkers for knee osteoarthritis by integrating human plasma proteome: evidence from Mendelian randomization and preliminary
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study sought to identify candidate plasma proteins with potential causal associations with knee osteoarthritis (KOA) through Mendelian randomization, and to provide preliminary biological evidence through Methods: Two-sample Mendelian randomization (MR) was conducted utilizing genetic instruments on 4,489 plasma proteins as exposures. Protein quantitative trait locus (pQTL) data were sourced from three large-scale studies. Genetic associations with KOA were obtained from a genome-wide association study (GWAS) of the European ancestry (accession ID: ebi-a-GCST007090; Results: Galectin-3 (encoded by LGALS3 [prot-b-6]) was identified as a biomarker of KOA (odds ratio [OR] = 1.07, 95% confidence interval [CI]:1.03-1.11, Conclusion: This study identifies galectin-3 as a preferred plasma protein biomarker of KOA. The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.